Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Some relief at St. Jude

WASHINGTON - The families of children who participated in a gene therapy trial at St. Jude Children's Research Hospital learned last week that the gene therapy product used in an experiment was not contaminated with HIV or hepatitis C.

Laura Bowman, the principal investigator in the trial, told BioCentury that FDA testing determined that the vaccine used in the study was not contaminated.

Read the full 628 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE